I think it is excellent news.
It’s another area of unmet need, recurrent solid tumors, and the pre-clinical data, especially the synergistic properties with immune checkpoint therapies is exciting!
The initial financial investment is fairly small and it says a lot about Kazia’s reputation and business development team that they were chosen as global partner.
Ann: Kazia licenses EVT801 from Evotec, page-10
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)